| 000 | 01677 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518050849.0 | ||
| 264 | 0 | _c20210601 | |
| 008 | 202106s 0 0 eng d | ||
| 022 | _a1573-0646 | ||
| 024 | 7 |
_a10.1007/s10637-019-00835-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJung, Su Young | |
| 245 | 0 | 0 |
_aPharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. _h[electronic resource] |
| 260 |
_bInvestigational new drugs _c06 2020 |
||
| 300 |
_a812-820 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAniline Compounds _xpharmacokinetics |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aReceptor, Transforming Growth Factor-beta Type I _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTriazoles _xpharmacokinetics |
| 700 | 1 | _aHwang, Sunjin | |
| 700 | 1 | _aClarke, Jeffery M | |
| 700 | 1 | _aBauer, Todd M | |
| 700 | 1 | _aKeedy, Vicki L | |
| 700 | 1 | _aLee, Hukeun | |
| 700 | 1 | _aPark, Neunggyu | |
| 700 | 1 | _aKim, Seong-Jin | |
| 700 | 1 | _aLee, Jangik I | |
| 773 | 0 |
_tInvestigational new drugs _gvol. 38 _gno. 3 _gp. 812-820 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10637-019-00835-y _zAvailable from publisher's website |
| 999 |
_c29896622 _d29896622 |
||